VEGFA and hepatocellular carcinoma: Recent work has shown increases in T cell infiltration following programmed death-ligand 1 (PD-L1) and VEGF blockade combination therapy in patients with hepatocellular carcinoma (HCC) and suggests that targeting VEGF potentially synergies mechanistically with PD-1/PD-L1 blockade.